• IBD-control increased significantly, indicating that patients reported higher levels of control over their disease.
• Self-reported physical activity and social connection increased overall.
• Self-reported wellbeing increased by an average of 17%.
• The overall sentiment from interviews was friendly, positive and encouraging and our courses and wellbeing content was received well by those both in flare and in remission.

• Patients taking the courses reported that they helped to change their behaviour through positively impacting their knowledge, beliefs about their capabilities, optimism, beliefs about the health and wellbeing consequences of self-management and their ability to set goals.
• Over 62% of patients reported that they had a positive attitude towards the course that they completed.
• Symptoms and disease activity measured on a validated Patient Reported Outcome Measure remained consistent throughout the trial.
• The overall positive response and acceptability of the technology, both from clinicians and subject matter experts is extremely promising.

We are a multi-award winning and social-impact focused company, developing personalised digital therapies for people living with long-term inflammatory conditions, created by our team of researchers, clinicians and patient groups.